NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Halia Therapeutics

Halia Therapeutics

Private
Lehi, UtahHealthcare & Life Scienceshttps://haliatx.com/

Last Round

Grant

Mar 11, 2025

Total Funding Raised

$41.34M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Halia Therapeutics is a biopharmaceutical company that develops novel therapies targeting inflammasome-driven disease biology to treat inflammatory disorders and neurological diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

NLRP3 inhibitorsmall-molecule therapydrug discoveryinflammasomebiotechclinical-stage biotechAI-driven drug discoveryneuroinflammationinflammatory diseasedrug pipelineclinical trialsin silico drug designAI drug discoverybiopharmatarget identification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Halia Therapeutics Comparables

Compare Halia Therapeutics with similar companies based on industry and business-model similarity.

Halia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ventus Therapeutics
86%
Olatec Therapeutics
85%
IFM Therapeutics
84%

Halia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 11, 2025
Series CJan 31, 2024
Series BFeb 17, 2021
Series AOct 22, 2020

Key People

Founding team and executive leadership

Jared Bearss

Chief Operating Officer - Co-Founder

Founding Team

David Bearss

Co-Founder, CEO, President And Chairman Of The Board

Founding Team

Jeff Burton

Chief Financial Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 17, 2026

    Monthly visitors grew 183% MoM, reaching 2.3K.

  • Mar 2, 2026

    Presenting at the BIO Investment & Growth Summit.

Halia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Halia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Halia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLehi, Utah
Employee Range27
Year Founded2017
Last FundingMar 11, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.